Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B

To the Editor Dr Choi and colleagues1 reported striking findings in 2 large-scale retrospective cohorts, which indicated that the risk of hepatocellular carcinoma (HCC) was lower in patients with chronic hepatitis B treated with tenofovir than entecavir. We have some concerns about this article.